• Explore /
  • Poster
  • / KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.

Abstract Video & Slides Poster

Authors

null

Conrad R. Jacobs

East Cape Onc, Cape Town, South Africa

Conrad R. Jacobs , Bernardo Leon Rapoport , Sze Wai Chan , Paul Ruff , Ana Maria Arance , Karmele Mujika , James Robert Anderson , Mallika Lala , Lokesh Jain , Omobolaji Oyekunle Akala , Elliot Chartash , Graham Lawrence Cohen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03665597

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9541)

DOI

10.1200/JCO.2021.39.15_suppl.9541

Abstract #

9541

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: ANA Maria Arance Fernandez

First Author: Richard S. Finn

First Author: Daniel Olson

First Author: Thomas Powles